Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Warfarin
Drug ID BADD_D02373
Description Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Indications and Usage **Indicated** for:[label,L6616] 1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism. 2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation. 3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement. 4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction. **Off-label** uses include: 1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]
Marketing Status approved
ATC Code B01AA03
DrugBank ID DB00682
KEGG ID D08682
MeSH ID D014859
PubChem ID 54678486
TTD Drug ID D0E3OF
NDC Product Code 76282-328; 43353-054; 65162-764; 70518-2381; 76282-335; 70518-2382; 76282-333; 43353-023; 51407-345; 65162-762; 65162-765; 70518-2383; 71335-1786; 65162-763; 65162-767; 68788-8402; 71610-491; 71610-519; 50090-2646; 50090-5058; 70518-2717; 71610-458; 71610-462; 43353-029; 50090-2936; 51407-346; 65162-769; 43353-030; 65162-768; 70518-2394; 71610-448; 71610-490; 76282-330; 50090-2613; 51407-342; 65162-766; 70518-2816; 76282-329; 76282-331; 76282-334; 50090-3263; 71335-1824; 76282-332; 43353-021; 43353-028; 43353-053; 51407-343; 51407-344; 51407-347; 65162-761; 76282-327; 43353-033; 50090-2645
UNII 5Q7ZVV76EI
Synonyms Warfarin | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one | Apo-Warfarin | Aldocumar | Gen-Warfarin | Warfant | Coumadin | Marevan | Warfarin Potassium | Potassium, Warfarin | Warfarin Sodium | Sodium, Warfarin | Coumadine | Tedicumar
Chemical Information
Molecular Formula C19H16O4
CAS Registry Number 81-81-2
SMILES CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thoracic haemorrhage24.07.01.082; 22.02.07.0170.000028%Not Available
Thyroid haemorrhage24.07.01.083; 05.02.01.0050.000042%Not Available
Portal venous gas07.01.06.0330.000028%Not Available
Basal ganglia haemorrhage24.07.04.021; 17.08.01.0390.000084%Not Available
Vasogenic cerebral oedema17.07.02.0080.000056%Not Available
Cerebral microhaemorrhage24.07.04.025; 17.08.02.0190.000042%Not Available
Abdominal wall haematoma07.16.05.005; 24.07.02.0390.001534%Not Available
Skin plaque23.03.03.0440.000028%Not Available
Dieulafoy's vascular malformation24.03.03.025; 07.15.04.0020.000090%Not Available
Cerebral amyloid angiopathy24.03.05.010; 17.08.02.017; 10.02.05.0030.000056%Not Available
Pharyngeal haematoma24.07.02.055; 22.04.05.016; 12.01.09.023--Not Available
Basal ganglia infarction24.04.06.028; 17.08.01.0400.000028%Not Available
Intestinal haematoma24.07.02.048; 07.12.03.0070.000435%Not Available
Herbal interaction08.06.03.005--Not Available
Superficial siderosis of central nervous system17.08.02.024; 14.13.03.007; 04.02.01.0160.000042%Not Available
Tumour rupture16.32.03.0330.000056%Not Available
Basal ganglia stroke24.04.06.029; 17.08.01.0410.000028%Not Available
Mesenteric haematoma12.01.17.013; 24.07.02.049; 07.12.03.0080.000154%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.000070%Not Available
Preterm premature rupture of membranes18.02.02.0160.000028%Not Available
Ophthalmic vein thrombosis24.01.05.011; 06.07.02.0070.000028%Not Available
Gastrointestinal polyp haemorrhage16.05.01.008; 24.07.02.046; 07.20.01.0110.000070%Not Available
Spontaneous haemorrhage24.07.01.081; 01.01.03.0070.000098%Not Available
Oral mucosa haematoma24.07.02.053; 07.05.02.0030.000042%Not Available
Internal haemorrhage24.07.01.0720.000098%Not Available
Chest wall haematoma15.03.05.005; 24.07.01.0650.000244%Not Available
Intracranial mass17.11.01.0170.000028%Not Available
Anisocoria17.02.11.009; 06.05.03.0130.000062%Not Available
Anticoagulant-related nephropathy20.05.03.023; 12.03.01.060; 24.07.07.0050.000379%Not Available
Atheroembolism12.02.05.052; 24.01.01.0370.000112%Not Available
The 22th Page    First    Pre   22 23 24    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene